Funding for this research was provided by:
Fru Berta Kamprads Stiftelse
Gunnar Nilssons Cancerstiftelse
Kungliga Fysiografiska Sällskapet i Lund
Percy Falks Stiftelse för Forskning Beträffande Prostata- och Bröstcancer
Received: 16 November 2020
Accepted: 31 January 2021
First Online: 18 February 2021
Ethics approval and consent to participate
: All clinical samples were coded to maintain patient confidentiality. The use of patient data and material was approved by the Regional Ethics Committee in Lund, Sweden (protocol number 2017/3) for the matched paired biopsies. For the patient cohort and samples used in immunohistochemical staining of cyclins E1 and E2 in the survival analysis, the use of patient data and material was approved by the Ethics Committee of the Region of Southern Ethics Committee of the Region of Southern Denmark (approval no. S-2008-0115) and the Danish Data Protection Agency (approval no. 2008-580035(14/10607)).
: Not applicable.
: AB is a member of Pfizer and Novartis advisory boards and has received travel support from Roche. SB has received speakers’ fees from Pfizer, is a member of a Pfizer advisory board, and has received travel support from Roche. AEh is on the Roche advisory board and has reported honoraria from Amgen, Novartis and Roche.